Trials / Not Yet Recruiting
Not Yet RecruitingNCT06674850
Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia
Assessment of the Prognostic Role of Systemic Inflammatory Index, Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
the goal of this observational study is Assesment of systemic inflammatory index (SII) , system inflammation response index (SIRI) and CRP Albumin ratio(CAR) as biomarkers for ALL prognosis.
Detailed description
Acute lymphoblastic leukemia (ALL) results from a clonal expansion of abnormal, immature lymphoid progenitors of B cell or T cell origin that invade bone marrow (BM), peripheral blood, and extramedullary sites . The incidence of ALL is highest among children aged 1-4 years and declines with age rising slightly after the age of 50. Several genetic alterations have been already found as drivers of ALL, uncovering the genetic heterogeneity of the disease. It is the most common leukemia in the pediatric population, according for up to 80% of cases in this group vs. 20% of cases in adults. Treatment among adolscents and young adults is predominantly inspired by pediatric regimens with better survival rates . Acute leukemia tends to present non-specifically, although the most common presenting features include fever, lethargy, and bleeding. Hepatosplenomegaly, lymphadenopathy, and musculoskeletal symptoms (especially involving the spine and long bones) can also be clues to the diagnosis. Adults may also have more prominent anemia-related symptoms, such as shortness of breath, or symptoms related to thrombocytopenia, such as excessive bruising or increased bleeding tendency.
Conditions
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2025-11-01
- Completion
- 2025-11-01
- First posted
- 2024-11-05
- Last updated
- 2024-11-05
Source: ClinicalTrials.gov record NCT06674850. Inclusion in this directory is not an endorsement.